Stanley Laman Group Ltd. Has $8.87 Million Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Stanley Laman Group Ltd. reduced its position in Schrödinger, Inc. (NASDAQ:SDGR) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,767 shares of the company’s stock after selling 11,316 shares during the quarter. Schrödinger accounts for approximately 1.4% of Stanley Laman Group Ltd.’s investment portfolio, making the stock its 10th largest holding. Stanley Laman Group Ltd. owned approximately 0.34% of Schrödinger worth $8,870,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of Schrödinger by 7.7% during the fourth quarter. ARK Investment Management LLC now owns 3,053,521 shares of the company’s stock valued at $109,316,000 after acquiring an additional 217,618 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Schrödinger by 60.3% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,300,750 shares of the company’s stock valued at $82,367,000 after acquiring an additional 865,867 shares in the last quarter. Illinois Municipal Retirement Fund acquired a new position in shares of Schrödinger during the third quarter valued at about $905,000. TrueMark Investments LLC acquired a new position in shares of Schrödinger during the fourth quarter valued at about $1,469,000. Finally, Avidity Partners Management LP increased its holdings in shares of Schrödinger by 45.1% during the third quarter. Avidity Partners Management LP now owns 399,000 shares of the company’s stock valued at $11,280,000 after acquiring an additional 124,100 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Schrödinger Stock Performance

Shares of NASDAQ SDGR traded down $0.70 during mid-day trading on Thursday, reaching $23.34. 917,561 shares of the company’s stock were exchanged, compared to its average volume of 849,621. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of 37.05 and a beta of 1.57. Schrödinger, Inc. has a 52-week low of $20.76 and a 52-week high of $59.24. The company’s 50-day moving average is $26.95 and its 200-day moving average is $28.28.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.12. The business had revenue of $74.10 million during the quarter, compared to analysts’ expectations of $79.12 million. Schrödinger had a negative return on equity of 23.58% and a net margin of 18.79%. The company’s revenue was up 30.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) EPS. As a group, equities analysts predict that Schrödinger, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SDGR has been the topic of a number of recent research reports. Bank of America dropped their target price on Schrödinger from $38.00 to $32.00 and set a “neutral” rating on the stock in a research report on Thursday, February 29th. KeyCorp lowered their price objective on Schrödinger from $38.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, February 29th. TD Cowen began coverage on Schrödinger in a research report on Friday, January 26th. They issued an “outperform” rating and a $42.00 price objective on the stock. Citigroup lowered their price objective on Schrödinger from $47.00 to $39.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Finally, Piper Sandler reduced their target price on Schrödinger from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.50.

Insider Activity at Schrödinger

In related news, insider Robert Lorne Abel sold 1,205 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $27.55, for a total transaction of $33,197.75. Following the completion of the transaction, the insider now directly owns 9,340 shares in the company, valued at approximately $257,317. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Kenneth Patrick Lorton sold 901 shares of Schrödinger stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $28.29, for a total value of $25,489.29. Following the completion of the transaction, the chief operating officer now owns 36,487 shares in the company, valued at approximately $1,032,217.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Robert Lorne Abel sold 1,205 shares of Schrödinger stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $27.55, for a total value of $33,197.75. Following the completion of the transaction, the insider now owns 9,340 shares of the company’s stock, valued at approximately $257,317. The disclosure for this sale can be found here. Insiders sold 3,651 shares of company stock worth $102,395 in the last three months. 7.60% of the stock is owned by company insiders.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.